| Chemical Information | |
| Antiviral agent ID | DrugRepV_0469 | |
| Antiviral agent name | Quinacrine |  |
| IUPAC Name | 4-N-(6-chloro-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine |  |
| SMILES (canonical) | CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC | |
| Molecular Formula | C23H30ClN3O | |
| Molecular Weight (g/mol) | 399.96 | |
| InChl | InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26) | |
| Common Name | Quinacrine | |
| Synonyms | 2-methoxy-6-chloro-9-diethylaminopentylaminoacridine | 3-chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine | 6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine | Mepacrine | N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-1,4-pentanediamine | |
| Structural Information | |
 |
|
| Clinical Information | |
|
Primary Indication (Clinical trial phases) | Investigational
|  |
| Biological Information | |
|
Primary Indication (Disease Category) | Infectious Disease
| |
|
Primary Indication (Disease) | Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions
| |
|
Secondary Indication | Ebola virus (EBOV) NA eGFP-EBOV |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | HepG2
| |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Viral titer) | 0.2 MOI
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | During inoculation
| |
|
Secondary Indication (Duration of drug delivery) | 48 hours
| |
|
Secondary Indication (Drug concentration) | 1.03 μM
| |
|
Secondary Indication (Cell based assay) | Fluorescence-based assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
|
Secondary Indication (Cytotoxicity) | 98.6 % | |
|
Reference | Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, S.A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activi.Sci Transl Med. 2015 Jun 3;7(290):290ra89. doi: 10.1126/scitranslmed.aaa5597. PMID:26041706
|  |
|
Comment | Antiviral activity was found for 80 U.S. Food and Drug Administration-approved drugs spanning multiple mechanistic classes, including selective estrogen receptor modulators, antihistamines, calcium channel blockers, and antidepressants. Results using an in vivo murine Ebola virus infection model confirmed the protective ability of several drugs, such as bepridil and sertraline. Viral entry assays indicated that most of these antiviral drugs block a late stage of viral entry. By nature of their approved status, these drugs have the potential to be rapidly advanced to clinical settings and used as therapeutic countermeasures for Ebola virus infections.
| |